Epigenetic drug boosts chemotherapy's efficacy in some lung cancers

lung cancer
Lung CA seen on CXR. Credit: CC BY-SA 4.0 James Heilman, MD/Wikipedia

An existing drug may help some patients with non-small-cell lung cancer (NSCLC) whose tumors have become resistant to chemotherapy, finds a study from Boston Children's Hospital and the Dana-Farber Cancer Institute (DFCI). The findings, in human cancer cells and in mice, suggest a window of vulnerability in NSCLC, the leading cause of cancer-related deaths worldwide.1 The work was published online today by the journal Nature.

NSCLC is a highly genetically complex with many different subtypes, each bearing different . In two common subtypes that do not respond to standard chemotherapy—tumors with BRG1 or EGFR mutations—the researchers increased the effectiveness of etoposide, a common chemotherapy agent, by adding an epigenetic already in clinical testing.

Conversely, when the same epigenetic therapy (inhibition of an enzyme known as EZH2) was added to certain tumors without BRG1 and EGFR mutations, the tumors become more resistant to chemotherapy. Together, the findings advance the idea of individualized, "precision medicine" in cancer, incorporating epigenetic therapy guided by tumor genetic testing.

The study also suggests that genetic tumor testing should screen for mutations in BRG1, a natural suppressor. This test is not done widely now, although testing does look for EGFR mutations and other known cancer "driver" mutations. An estimated 10 percent of patients with NSCLC have BRG1 mutations, and this genetic subtype currently lacks a targeted therapy.

"Etoposide plus an EZH2 inhibitor could be a first-line therapy for BRG1-mutant tumors, and a treatment option for EGFR-mutant tumors that are resistant to tyrosine kinase inhibitors," says Christine Fillmore, PhD, of Boston Children's Hospital's Stem Cell Research Program, the study's first author.

EZH2 has been strongly linked with cancer progression and is part of a complex of molecules that determine which genes in a cell are turned "on" or "off"—part of the cell's so-called epigenome. Epigenetic therapy has become a hot area in cancer research, and EZH2 inhibitors are in phase I/II trials for other cancers, including B cell lymphomas and malignant rhabdoid tumors.

However, the use of EZH2 inhibitors in has needed more rationale in preclinical studies, says oncologist Kwok-Kin Wong, MD, PhD, professor of medicine at DFCI and Harvard Medical School and a collaborator on the study. The researchers hope their findings will inspire the pharmaceutical industry to test EZH2 inhibitors together with in patients whose tumors have BRG1 or EGFR mutations.

"This study provides better predictive information as to which cancer patients will respond to EZH2 inhibitors, and shows that even epigenetic therapy needs to be specified to a genotype," says senior author Carla Kim, PhD, an associate professor at Boston Children's Stem Cell Program and the Department of Genetics at Harvard Medical School.

"We don't have to invent new drugs. The drugs are already out there," adds Wong. "That's the great thing."

More information: Paper: EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors, Nature, DOI: 10.1038/nature14122

1. Jemal, A. et al. Global cancer statistics. CA: A Cancer Journal for Clinicians 61, 69-90, DOI: 10.3322/caac.20107 (2011).

Journal information: Nature
Citation: Epigenetic drug boosts chemotherapy's efficacy in some lung cancers (2015, January 28) retrieved 19 March 2024 from https://medicalxpress.com/news/2015-01-epigenetic-drug-boosts-chemotherapy-efficacy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Key factor discovered in the formation of metastases in melanoma

84 shares

Feedback to editors